Company Overview - Oculis Holding AG (OCS) is expected to report a year-over-year decline in earnings with a projected loss of $0.51 per share, reflecting a change of -15.9% compared to the previous year [3] - Revenues are anticipated to remain flat at $0.22 million, unchanged from the year-ago quarter [3] Earnings Expectations - The consensus EPS estimate has been revised 5.01% higher in the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for Oculis is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -7.32%, suggesting a bearish outlook on earnings prospects [10][11] Historical Performance - Oculis has not been able to beat consensus EPS estimates in any of the last four quarters, with the last reported quarter showing a surprise of -58.33% [12][13] Market Reaction - The stock may experience upward movement if the actual results exceed expectations, while a miss could lead to a decline [2] - The combination of a negative Earnings ESP and a Zacks Rank of 3 makes it challenging to predict an earnings beat for Oculis [11][16]

Core Insights - Oculis Holding AG is a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs [4] Upcoming Conferences - Oculis will present at several investor conferences, including Bio€quity Europe from May 12-14, 2025, where CEO Riad Sherif will provide a company update on May 14 at 11am CET [1] - The company will also participate in the Bank of America Healthcare Conference from May 13-15, 2025, with CFO Sylvia Cheung engaging in a fireside chat on May 14 at 3pm PT [2] - Additional presentations include the H.C. Wainwright Annual BioConnect at Nasdaq on May 20, 2025, and the Stifel Virtual Ophthalmology Forum on May 27, 2025, both featuring updates from CFO Sylvia Cheung [2] Company Pipeline - Oculis has a differentiated pipeline of innovative product candidates, including OCS-01 for diabetic macular edema, Privosegtor (OCS-05) for acute optic neuritis, and Licaminlimab (OCS-02) for dry eye disease [4]

Core Insights - Oculis Holding AG is a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs [5] Upcoming Conferences - Oculis will present at several investor conferences, including Bio€quity Europe from May 12-14, 2025, where CEO Riad Sherif will provide a company update on May 14 at 11am CET [1] - The company will also participate in the Bank of America Healthcare Conference from May 13-15, 2025, featuring a fireside chat with CFO Sylvia Cheung on May 14 at 3pm PT [2] - Additional presentations include the H.C. Wainwright Annual BioConnect at Nasdaq on May 20, 2025, and the Stifel Virtual Ophthalmology Forum on May 27, 2025, both featuring updates from CFO Sylvia Cheung [2] Company Pipeline - Oculis has a differentiated pipeline that includes OCS-01, a topical eye drop candidate for diabetic macular edema (DME); Privosegtor (OCS-05), a neuroprotective candidate for acute optic neuritis; and Licaminlimab (OCS-02), a topical biologic anti-TNFα eye drop candidate for dry eye disease (DED) [5]

Core Insights - Oculis Holding AG is presenting its innovative late-stage pipeline at major ophthalmology conferences, including Eyecelerator 2025, ARVO Annual Meeting, and Retina World Congress [1][2][3] Pipeline Developments - The DME AWARE Delphi Study interim results will focus on unmet needs in diabetic macular edema (DME) patient management, with insights from the Phase 3 DIAMOND program on OCS-01 eye drops [2][7] - OCS-01 is being developed as the first non-invasive treatment for DME, addressing the need for earlier intervention and for patients who do not respond adequately to current treatments [2][13] - Licaminlimab (OCS-02) is being investigated for dry eye disease (DED) and has shown positive results in Phase 2 trials, with a genetic biomarker identified to predict patient response [3][16] Conference Presentations - Oculis will showcase its developments at the following events: - Eyecelerator 2025 on May 2, 2025, featuring TKI and Drug Delivery [4] - ARVO Annual Meeting on May 5, 2025, presenting interim results of the DME AWARE Delphi Study [7] - Retina World Congress on May 8, 2025, discussing Licaminlimab in DED treatment [7] Market Context - DME currently affects approximately 37 million people globally, with projections to rise to 53 million by 2040 due to increasing diabetes prevalence [15] - DED impacts over 110 million people in G7 countries, with a significant portion of patients remaining unsatisfied with current treatment options [18][19] Company Overview - Oculis is a biopharmaceutical company focused on addressing significant unmet medical needs in ophthalmic and neuro-ophthalmic diseases, with a pipeline that includes OCS-01 for DME and Licaminlimab for DED [20]

Company Overview - Oculis Holding AG is a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs [20] - The company is developing a differentiated pipeline of innovative product candidates, including OCS-01 for diabetic macular edema (DME) and Licaminlimab for dry eye disease (DED) [20] Upcoming Presentations - Oculis will present its late-stage pipeline at several key conferences, including Eyecelerator 2025, ARVO Annual Meeting, and Retina World Congress [1][2][3] - The presentations will cover interim results from the DME AWARE Delphi Study and insights from the Phase 3 DIAMOND program regarding OCS-01 eye drops for DME [2][3] Product Details - OCS-01 is an investigational eye drop formulation designed to treat DME non-invasively, aiming to transform the treatment paradigm by providing an alternative to invasive methods like intravitreal injections [13][14] - Licaminlimab (OCS-02) is being developed as a topical biologic anti-TNFα eye drop for DED, with a focus on personalized treatment approaches based on genetic biomarkers [16][19] Market Context - DME currently affects approximately 37 million people globally, with projections to rise to 53 million by 2040 due to increasing diabetes prevalence [15] - DED impacts over 110 million people in G7 countries, with a significant portion of patients remaining unsatisfied with current treatment options [18][19]

ZUG, Switzerland, April 25, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company, has issued registered ordinary shares of the Company, each with a nominal value of CHF 0.01. The issuance comprises 589,974 registered shares, reflecting the settlement of 310,941 shares issued in connection with the exercise of equity awards under the Company’s Stock Option and Incentive Plan Regulation and 279,033 shares issued through EBAC warran ...

Core Points - Oculis Holding AG announces the continuation of the Ramin Tadayoni Award in collaboration with EURETINA to honor the legacy of Professor Tadayoni, focusing on innovative research in retinal diseases [1][2] - The award provides €30,000 for research support and an additional €5,000 for the candidate, aimed at postgraduate scholars in retina research, with applications open until May 12, 2025 [3] - The inaugural recipient of the award in 2024 was Dr. Andrea Govetto, who is developing a computational model for macular edema [4] Company Overview - Oculis is a global biopharmaceutical company focused on ophthalmic and neuro-ophthalmic diseases, with a pipeline that includes OCS-01 for diabetic macular edema, Privosegtor for acute optic neuritis, and Licaminlimab for dry eye disease [6] - The company is headquartered in Switzerland and operates in the U.S. and Iceland, led by an experienced management team supported by international healthcare investors [6]

Core Insights - Oculis Holding AG is hosting an R&D Day to update on its late-stage clinical candidates and future development strategies [1][2] - The event will feature key opinion leaders and will include a live Q&A session [2][3] Company Overview - Oculis is a global biopharmaceutical company focused on ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs [5] - The company has a differentiated pipeline including OCS-01 for diabetic macular edema, Privosegtor for acute optic neuritis, and Licaminlimab for dry eye disease [5] Clinical Development Updates - Enrollment for the Phase 3 DIAMOND trials of OCS-01 has been completed with over 800 patients, and topline data is expected in Q2 2026 [6] - Licaminlimab's Phase 2/3 study is anticipated to start in the second half of 2025, focusing on a personalized approach to dry eye disease [6] - Expanded data analysis from the ACUITY Phase 2 trial for Privosegtor will be discussed, along with new programs for treating non-arteritic anterior ischemic optic neuritis and multiple sclerosis [6]

Core Viewpoint - Oculis Holding AG is hosting an R&D Day to provide updates on its late-stage clinical candidates and future development strategies, emphasizing its commitment to addressing unmet medical needs in ophthalmic and neuro-ophthalmic diseases [1][2]. Group 1: Event Details - The R&D Day will take place on April 15, 2025, from 10:00 AM to 12:00 PM ET at the Intercontinental New York Barclay hotel, with options for in-person and virtual attendance [1]. - The event will include presentations from key opinion leaders and a live Q&A session following the formal presentations [2][3]. Group 2: Clinical Pipeline Updates - Oculis will provide updates on three innovative late-stage clinical candidates: OCS-01 for diabetic macular edema (DME), Licaminlimab (OCS-02) for dry eye disease (DED), and Privosegtor (OCS-05) for acute optic neuritis [5][6]. - Enrollment for the Phase 3 DIAMOND trials of OCS-01 has been completed with over 800 patients, and topline data is expected in Q2 2026 [6]. - The development plan for Licaminlimab (OCS-02) aims to adopt a genotype-based personalized approach in DED, with a Phase 2/3 study anticipated to start in the second half of 2025 [6]. Group 3: Future Development Plans - Oculis will announce two new programs utilizing Privosegtor (OCS-05) for treating non-arteritic anterior ischemic optic neuritis (NAION) and for managing acute relapses in multiple sclerosis (MS) patients [6]. - The company is focused on maximizing resources and driving value through its portfolio prioritization strategy [2]. Group 4: Upcoming Investor Meeting - An investor meeting will be held in Iceland on April 29, 2025, where Oculis management and ophthalmology experts will discuss the late-stage pipeline [4].

Core Insights - Oculis Holding AG has completed enrollment in Phase 3 DIAMOND-1 and DIAMOND-2 trials for OCS-01 eye drops targeting diabetic macular edema (DME), with over 800 patients enrolled across 119 sites [1][2][7] - Topline data from these trials is expected in Q2 2026, followed by a New Drug Application (NDA) submission to the FDA [2][4][10] - If approved, OCS-01 will be the first topical eye drop treatment for DME, addressing significant unmet medical needs [3][6] Company Overview - Oculis is a global biopharmaceutical company focused on innovative treatments for ophthalmic and neuro-ophthalmic diseases [1][11] - The company is developing OCS-01 as a non-invasive alternative to current invasive treatments for DME, which typically require injections [6][11] - Oculis' proprietary OPTIREACH technology enhances drug delivery to the retina, improving treatment accessibility [6][11] Industry Context - DME is a leading cause of visual loss and legal blindness among diabetic patients, currently affecting approximately 37 million people globally, with projections of 53 million by 2040 [9] - There is a critical need for effective and less burdensome treatments for DME, as existing therapies often involve invasive procedures [9][10]